402 related articles for article (PubMed ID: 37074485)
1. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
[TBL] [Abstract][Full Text] [Related]
2. Targeting phosphodiesterase 4 as a potential therapy for Parkinson's disease: a review.
Nongthombam PD; Haobam R
Mol Biol Rep; 2024 Apr; 51(1):510. PubMed ID: 38622307
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
4. Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?
Nthenge-Ngumbau DN; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):822-834. PubMed ID: 28062949
[TBL] [Abstract][Full Text] [Related]
5. PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Kenk M; Thomas A; Lortie M; Dekemp R; Beanlands RS; Dasilva JN
Curr Radiopharm; 2011 Jan; 4(1):44-58. PubMed ID: 22191614
[TBL] [Abstract][Full Text] [Related]
6. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
Ookawara M; Nio Y
Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
10. Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias.
Molina CE; Leroy J; Richter W; Xie M; Scheitrum C; Lee IO; Maack C; Rucker-Martin C; Donzeau-Gouge P; Verde I; Llach A; Hove-Madsen L; Conti M; Vandecasteele G; Fischmeister R
J Am Coll Cardiol; 2012 Jun; 59(24):2182-90. PubMed ID: 22676938
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
Zhong J; Yu H; Huang C; Zhong Q; Chen Y; Xie J; Zhou Z; Xu J; Wang H
Redox Biol; 2018 Jun; 16():47-58. PubMed ID: 29475134
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Padovan-Neto FE; West AR
Adv Neurobiol; 2017; 17():257-283. PubMed ID: 28956336
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibitors for disease therapy: advances and future perspective.
Du B; Luo M; Ren C; Zhang J
Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.
Patel BS; Prabhala P; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2015 May; 52(5):634-40. PubMed ID: 25296132
[TBL] [Abstract][Full Text] [Related]
16. Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.
Vinogradova TM; Sirenko S; Lukyanenko YO; Yang D; Tarasov KV; Lyashkov AE; Varghese NJ; Li Y; Chakir K; Ziman B; Lakatta EG
Circ Arrhythm Electrophysiol; 2018 Jun; 11(6):e005896. PubMed ID: 29880528
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice.
Zhang FF; Wang H; Zhou YM; Yu HY; Zhang M; Du X; Wang D; Zhang F; Xu Y; Zhang JG; Zhang HT
CNS Neurosci Ther; 2022 May; 28(5):749-760. PubMed ID: 35156776
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Keravis T; Monneaux F; Yougbaré I; Gazi L; Bourguignon JJ; Muller S; Lugnier C
PLoS One; 2012; 7(1):e28899. PubMed ID: 22247763
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
[TBL] [Abstract][Full Text] [Related]
20. Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model.
Mika D; Bobin P; Lindner M; Boet A; Hodzic A; Lefebvre F; Lechène P; Sadoune M; Samuel JL; Algalarrondo V; Rucker-Martin C; Lambert V; Fischmeister R; Vandecasteele G; Leroy J
J Mol Cell Cardiol; 2019 Aug; 133():57-66. PubMed ID: 31158360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
